Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6

Despite direct viral effect, the pathogenesis of coronavirus disease 2019 (COVID-19) includes an overproduction of cytokines including interleukin 6 (IL-6). Therefore, tocilizumab (TOC), a monoclonal antibody against IL-6 receptors, was considered as a possible therapeutic option. Patients were sele...

Descripción completa

Detalles Bibliográficos
Autores principales: Flisiak, Robert, Jaroszewicz, Jerzy, Rogalska, Magdalena, Łapiński, Tadeusz, Berkan-Kawińska, Aleksandra, Bolewska, Beata, Tudrujek-Zdunek, Magdalena, Kozielewicz, Dorota, Rorat, Marta, Leszczyński, Piotr, Kłos, Krzysztof, Kowalska, Justyna, Pabjan, Paweł, Piekarska, Anna, Mozer-Lisewska, Iwona, Tomasiewicz, Krzysztof, Pawłowska, Małgorzata, Simon, Krzysztof, Polanska, Joanna, Zarębska-Michaluk, Dorota
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070099/
https://www.ncbi.nlm.nih.gov/pubmed/33918563
http://dx.doi.org/10.3390/jcm10081583

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070099/
https://www.ncbi.nlm.nih.gov/pubmed/33918563
http://dx.doi.org/10.3390/jcm10081583

Ejemplares similares